Trelegy Shortage Update for 2026: What's Going On?

If you've had trouble filling your Trelegy Ellipta prescription recently, you're probably wondering: is there an actual shortage? The answer is nuanced — and important to understand so you can take the right steps to keep your treatment on track.

In this update, we'll cover the current status of Trelegy availability, why it's been hard to find, what it costs in 2026, and how to get your inhaler filled.

Is Trelegy Still in Shortage?

As of early 2026, Trelegy Ellipta is not listed on the FDA's official drug shortage database. This means there is no declared nationwide manufacturing shortage from GlaxoSmithKline (GSK).

However, that doesn't tell the whole story. Many patients across the country have reported intermittent difficulty finding Trelegy at their local pharmacies. These availability gaps are real — they're just not caused by a single, centralized supply failure. Instead, they result from a combination of factors that create localized and temporary stockouts.

Why Is Trelegy Hard to Find?

Several factors are contributing to the difficulty patients face when trying to fill their Trelegy prescriptions:

• High and growing demand: Trelegy is one of the most prescribed maintenance inhalers in the U.S. As more providers prescribe triple therapy for COPD and asthma, pharmacy shelves get depleted faster.
• No generic competition: With no generic version of Trelegy available, all supply comes from GSK. Any distribution hiccup creates a bottleneck with no alternative supply source.
• Insurance hurdles: Prior authorization and step therapy requirements mean many patients face delays that compound the perception of a shortage.
• Supply chain variability: Different pharmacy chains source from different distributors, leading to uneven availability across locations — even within the same city.

For a deeper dive into these causes, read why Trelegy is so hard to find in 2026.

How Much Does Trelegy Cost in 2026?

Trelegy Ellipta remains one of the more expensive maintenance inhalers on the market:

• Cash price (without insurance): approximately $580 to $700 for one inhaler (30-day supply)
• With commercial insurance: copays typically range from $30 to $75 per month, depending on your plan's formulary tier
• With Medicare Part D: costs vary widely based on your plan and which phase of coverage you're in; many patients pay $50 to $150+ per month

If cost is a barrier, GSK offers a Trelegy Savings Card that can reduce copays to as low as $0 per month for commercially insured patients. GSK also runs a Patient Assistance Program (GSK For You) for uninsured or underinsured patients who meet income qualifications.

Read our full guide on how to save money on Trelegy in 2026 for more options.

Are There New Options for COPD and Asthma Patients?

The respiratory medication landscape continues to evolve. Here's what patients should know about alternatives:

• Breztri Aerosphere remains the only other FDA-approved triple-combination inhaler for COPD. If you can't get Trelegy, Breztri may be covered on your plan.
• Dual-inhaler combinations — such as Breo Ellipta (ICS/LABA) plus Incruse Ellipta (LAMA) — can replicate Trelegy's triple therapy with two devices.
• Generic Symbicort (Budesonide/Formoterol) offers a more affordable ICS/LABA option that can be paired with a LAMA for triple therapy on a budget.

Learn more about your options in our alternatives to Trelegy guide.

How to Find Trelegy in Stock

Here are the best strategies to locate Trelegy Ellipta near you:

1. Use Medfinder to check real-time pharmacy availability based on your zip code.
2. Try independent pharmacies that may have different supply chains than major chains.
3. Request refills 7–14 days early to give your pharmacy time to order.
4. Ask about mail-order options through your insurance plan for 90-day supplies.
5. Expand your search radius — pharmacies in neighboring towns may have stock when yours doesn't.

For a detailed walkthrough, see how to find Trelegy in stock near you.

Final Thoughts

While Trelegy Ellipta isn't in a formal nationwide shortage in 2026, real-world availability remains inconsistent for many patients. The combination of high demand, no generic alternative, and insurance complexity means you may need to be proactive about finding and affording your medication.

Don't skip doses, don't ration your inhaler, and don't wait until you're out to start looking. Use the tools and strategies above to stay ahead of supply issues, and talk to your doctor if you're having ongoing difficulty — they can help you find alternatives or navigate insurance barriers.

Your lungs don't take days off. Your treatment shouldn't either.